

A million and of experience...

Give or take a billion

You've had more experience with Dalmane (flurazepam HCl/Roche) than with any other benzodiazepine hypnotic... 15 years' worth.

You know you can *count* on it for sleep that satisfies patients—they fall asleep quickly and sleep through the night.¹⁻⁸ And the wide margin of safety with Dalmane^{7,9} satisfies *you*. As always, caution patients about driving or drinking alcohol.





1 nights

DALMANE[®]
flurazepam HCl/Roche[®]
sleep that satisfies

Please see following page for references and summary of product information.

References: 1. Kales J, et al: *Clin Pharmacol Ther* 12:691-697, Jul-Aug 1971. 2. Kales A, et al: *Clin Pharmacol Ther* 18:356-363, Sep 1975. 3. Kales A, et al: *Clin Pharmacol Ther* 19:576-583, May 1976. 4. Kales A, et al: *Clin Pharmacol Ther* 32:781-788, Dec 1982. 5. Frost JD Jr, DeLucchi MR: *J Am Geriatr Soc* 27:541-546, Dec 1979. 6. Dement WC, et al: *Behav Med*, pp. 25-31, Oct 1978. 7. Kales A, Kales JD: *J Clin Psychopharmacol* 3:140-150, Apr 1983. 8. Tennant FS, et al: Symposium on the Treatment of Sleep Disorders, Teleconference, Oct 16, 1984. 9. Greenblatt DJ, Allen MD, Shader RI: *Clin Pharmacol Ther* 21:355-361, Mar 1977.

DALMANE®
flurazepam HCl/Roche®
sleep that satisfies

15-mg/30-mg capsules



Before prescribing, please consult complete product information, a summary of which follows:

Indications: Effective in all types of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening; in patients with recurring insomnia or poor sleeping habits; in acute or chronic medical situations requiring restful sleep. Objective sleep laboratory data have shown effectiveness for at least 28 consecutive nights of administration. Since insomnia is often transient and intermittent, prolonged administration is generally not necessary or recommended. Repeated therapy should only be undertaken with appropriate patient evaluation.

Contraindications: Known hypersensitivity to flurazepam HCl; pregnancy. Benzodiazepines may cause fetal damage when administered during pregnancy. Several studies suggest an increased risk of congenital malformations associated with benzodiazepine use during the first trimester. Warn patients of the potential risks to the fetus should the possibility of becoming pregnant exist while receiving flurazepam. Instruct patients to discontinue drug prior to becoming pregnant. Consider the possibility of pregnancy prior to instituting therapy.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. An additive effect may occur if alcohol is consumed the day following use for nighttime sedation. This potential may exist for several days following discontinuation. Caution against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Potential impairment of performance of such activities may occur the day following ingestion. Not recommended for use in persons under 15 years of age. Withdrawal symptoms rarely reported; abrupt discontinuation should be avoided with gradual tapering of dosage for those patients on medication for a prolonged period of time. Use caution in administering to addiction-prone individuals or those who might increase dosage.

Precautions: In elderly and debilitated patients, it is recommended that the dosage be limited to 15 mg to reduce risk of oversedation, dizziness, confusion and/or ataxia. Consider potential additive effects with other hypnotics or CNS depressants. Employ usual precautions in severely depressed patients, or in those with latent depression or suicidal tendencies, or in those with impaired renal or hepatic function.

Adverse Reactions: Dizziness, drowsiness, lightheadedness, staggering, ataxia and falling have occurred, particularly in elderly or debilitated patients. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdosage, have been reported. Also reported: headache, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, GI pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and GU complaints. There have also been rare occurrences of leukopenia, granulocytopenia, sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations, and elevated SGOT, SGPT, total and direct bilirubins, and alkaline phosphatase, and paradoxical reactions, e.g., excitement, stimulation and hyperactivity.

Dosage: Individualize for maximum beneficial effect. **Adults:** 30 mg usual dosage, 15 mg may suffice in some patients. **Elderly or debilitated patients:** 15 mg recommended initially until response is determined.

Supplied: Capsules containing 15 mg or 30 mg flurazepam HCl.



Roche Products Inc.
Manati, Puerto Rico 00701

ORTHOPAEDIC SURGEON ENT-FACIOPLASTIC PSYCHIATRIST INTERNAL MEDICINE

General Med is a rapidly growing staff model Health Maintenance Organization (HMO) with 30 well-appointed medical offices in beautiful Southern California. We provide a professional environment, competitive salary and excellent benefit package including employer paid vacation, CME time, malpractice and pension plan. If you are Board certified (or eligible) and California licensed, General Med would like to discuss professional career opportunities with you.

Please send your CV to:

Nancy Boostrom
GENERAL MED

701 South Parker Street, Suite 5000
Orange, California 92668

The Western Journal of Medicine

(ISSN 0093-0415/USPS 084 480) is published monthly for \$20 per year (USA and Canada) by the California Medical Association, P.O. Box 7602, San Francisco, CA 94120-7602. Second-class postage paid at San Francisco, CA and additional mailing offices.

POSTMASTER: Send address changes to *The Western Journal of Medicine*, Circulation, P.O. Box 7602, San Francisco, CA 94120-7602.

Moving?

Please give us six weeks notice and supply your personal reference number.

ID No.

The Western Journal of Medicine
P.O. Box 7602
San Francisco, CA 94120-7602.


302703 XX

The Western Journal of Medicine

P.O. Box 7602, San Francisco, CA 94120-7602

Motrin[®] 800 TABLETS mg

ibuprofen



Extra strength
Convenience
Economy


Upjohn



A Century
of Caring
1886-1986

The New Look of
Medrol[®] Dosepak[™] Unit of Use
4 mg methylprednisolone tablets, USP

The explicit printed dosage instructions that accompany each *Dosepak* make it easy for the patient to understand and follow the dosage regimen.



Before prescribing, see complete prescribing information in SK&F CO. literature or PDR. The following is a brief summary.

*** WARNING**

This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Concomitant use with other potassium-sparing agents such as spironolactone or amiloride. Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K^+ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K^+ intake. Associated widened QRS complex or arrhythmia requires prompt additional therapy. Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: The bioavailability of the hydrochlorothiazide component of 'Dyazide' is about 50% of the bioavailability of the single entity. Theoretically, a patient transferred from the single entities of Dyrenium (triamterene, SK&F CO.) and hydrochlorothiazide may show an increase in blood pressure or fluid retention. Similarly, it is also possible that the lesser hydrochlorothiazide bioavailability could lead to increased serum potassium levels. However, extensive clinical experience with 'Dyazide' suggests that these conditions have not been commonly observed in clinical practice. Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids, and during concurrent use with amphotericin B or corticosteroids or corticotropin [ACTH]). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate coma in patients with severe liver disease. Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic and hemolytic anemia have been reported with thiazides. Thiazides may cause manifestation of latent diabetes mellitus. The effects of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. Clinically insignificant reductions in arterial responsiveness to norepinephrine have been reported. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effects may be enhanced in post-sympathectomy patients. Use cautiously in surgical patients. Triamterene has been found in renal stones in association with the other usual calculus components. Therefore, 'Dyazide' should be used with caution in patients with histories of stone formation. A few occurrences of acute renal failure have been reported in patients on 'Dyazide' when treated with indomethacin. Therefore, caution is advised in administering nonsteroidal anti-inflammatory agents with 'Dyazide'. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia is uncommon with 'Dyazide', but should it develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances; postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and respiratory distress including pneumonitis and pulmonary edema, transient blurred vision, sialadenitis, and vertigo have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components. Rare incidents of acute interstitial nephritis have been reported. Impotence has been reported in a few patients on 'Dyazide', although a causal relationship has not been established.

Supplied: 'Dyazide' is supplied as a red and white capsule, in bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

BRS-DZ:L39

a product of

SK&F CO.

Carolina, P.R. 00630

© SK&F Co., 1985

The unique
red and white
Dyazide® capsule:
Your assurance of
SK&F quality.



In Hypertensives Over 50, Diuretics Are Preferred

The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends diuretics as the favored monotherapy in patients over 50 years of age, regardless of sex or race.



Beta Blockers Aren't for Everyone...
For Hypertensive Patients* Over 50

P R E S C R I B E

®

25 mg Hydrochlorothiazide/50 mg Triamterene/SKF

Used with Confidence for over 19 Years

Serum K^+ and BUN should be checked periodically (see Warnings and Precautions).

In hypertension **CORGARD®** (nadolol tablets)



CORGARD® TABLETS Nadolol Tablets

DESCRIPTION: Corgard (nadolol) is a synthetic nonselective beta-adrenergic receptor blocking agent.

CONTRAINDICATIONS: Bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see WARNINGS). **WARNINGS:** **Cardiac Failure**—Sympathetic stimulation may be a vital component supporting circulatory function in congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle. IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure; therefore, at first sign or symptom of heart failure, digitalize and/or give diuretics, and closely observe response, or discontinue nadolol (gradually if possible).

Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal—

Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronic use of nadolol, particularly in patients with ischemic heart disease, gradually reduce dosage over a 1- to 2-week period and carefully monitor the patient. Reinstitute nadolol promptly (at least temporarily) and take other measures appropriate for management of unstable angina if angina markedly worsens or acute coronary insufficiency develops. Warn patients not to interrupt or discontinue therapy without physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)—PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Administer nadolol with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta₂ receptors.

Major Surgery—Because beta-blockade impairs the ability of the heart to respond to reflex stimuli and may increase risks of general anesthesia and surgical procedures, resulting in protracted hypotension or low cardiac output, it has generally been suggested that such therapy should be withdrawn several days prior to surgery. Recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. If possible, withdraw beta-blockers well before surgery takes place. In emergency surgery, inform the anesthesiologist that the patient is on beta-blocker therapy. Use of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or levaterenol can reverse the effects of nadolol. Difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents.

Diabetes and Hypoglycemia—Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust dose of antidiabetic drugs.

Thyrotoxicosis—Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. To avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm, carefully manage patients suspected of developing thyrotoxicosis.

PRECAUTIONS: Impaired Renal Function—Use nadolol with caution (see DOSAGE AND ADMINISTRATION section of package insert).

Information for Patients—Warn patients, especially those with evidence of coronary artery insufficiency, against interruption or discontinuation of nadolol without physician's advice. Although cardiac failure rarely occurs in properly selected patients, advise patients being treated with beta-adrenergic blocking agents to consult physician at first sign of impending failure. Advise patients in event of missed doses.

Drug Interactions—Concurrent administration may result in interactions with: Anesthetics, general—exaggeration of the hypotension induced by general anesthetics (see WARNINGS, Major Surgery). Antidiabetic drugs (oral agents and insulin)—hypoglycemia or hyperglycemia; adjust antidiabetic drug dosage accordingly (see WARNINGS, Diabetes and Hypoglycemia). Catecholamine-depleting drugs (e.g., reserpine)—additive effect; monitor closely for hypotension and/or excessive bradycardia.

Carcinogenesis, Mutagenesis, Impairment of Fertility—In 1 to 2 years' oral toxicologic studies in mice, rats, and dogs, nadolol did not produce significant toxic effects. In 2-year oral carcinogenic studies in rats and mice, nadolol did not produce neoplastic, preneoplastic, or nonneoplastic pathologic lesions.

Pregnancy—In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits (but not in rats or hamsters) at doses 5 to 10 times greater (on a mg/kg basis) than maximum indicated human dose; no teratogenic potential was seen in any of these species. There are no well-controlled studies in pregnant women; therefore, use nadolol in pregnant women only if potential benefit justifies potential risk to the fetus. Neonates of mothers who received nadolol at parturition have exhibited bradycardia, hypoglycemia and associated symptoms.

Nursing Mothers—Nadolol is excreted in human milk. Exercise caution when nadolol is administered to a nursing woman.

Pediatric Use—Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: Most adverse effects have been mild and transient and have rarely required nadolol withdrawal.

Cardiovascular—Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). **Central Nervous System**—Dizziness or fatigue reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior reported in approximately 6 of 1000 patients.

Respiratory—Bronchospasm reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS). **Gastrointestinal**—Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating and flatulence each reported in 1 to 5 of 1000 patients. **Miscellaneous**—Each of the following reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision; infrequent reversible alopecia. The following adverse reactions have been reported in patients taking nadolol and/or other beta-adrenergic blocking agents, but no causal relationship to nadolol has been established.

Central Nervous System—reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place; short-term memory loss, emotional lability with slightly clouded sensorium; decreased performance on neuropsychometrics. **Gastrointestinal**—mesenteric arterial thrombosis; ischemic colitis; elevated liver enzymes. **Hematologic**—agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura. **Allergic**—fever combined with aching and sore throat; laryngospasm; respiratory distress. **Miscellaneous**—pemphigoid rash; hypertensive reaction in patients with pheochromocytoma; sleep disturbances; Peyronie's disease. The oculomucocutaneous syndrome associated with pralolol has not been reported with nadolol.

OVERDOSAGE: Nadolol can be removed from the general circulation by hemodialysis. In addition to gastric lavage, employ the following measures as appropriate. In determining duration of corrective therapy, take note of long duration of effect of nadolol.

Excessive Bradycardia—Administer atropine (0.25 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.

Cardiac Failure—Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation.

Hypotension—Administer vasopressors, e.g., epinephrine or levaterenol. (There is evidence that epinephrine may be the drug of choice.)

Bronchospasm—Administer a beta₂-stimulating agent and/or a theophylline derivative. **DOSAGE:** For all patients, DOSAGE MUST BE INDIVIDUALIZED.

For **angina pectoris**, usual initial dose is 40 mg q.d.; may be gradually increased in 40 to 80 mg increments at 3 to 7 day intervals until optimum clinical response or pronounced slowing of the heart rate; usual maintenance dose is 40 or 80 mg q.d. (doses up to 160 or 240 mg daily may be needed). If treatment is to be discontinued, reduce dosage gradually over a period of 1 to 2 weeks (see WARNINGS).

For **hypertension**, usual initial dose is 40 mg q.d.; gradually increase in 40 to 80 mg increments until optimum blood pressure reduction is achieved; usual maintenance dose is 40 or 80 mg q.d. (doses up to 240 or 320 mg daily may be needed).

Patients with renal failure require adjustment in dosing interval; see package insert for dosage in these patients.

For full prescribing information, consult package insert.

HOW SUPPLIED: In scored tablets containing 40, 80, 120, or 160 mg nadolol per tablet in bottles of 100 and in Unimatic* unit-dose packs of 100 tablets. The 40 mg, 80 mg, and 120 mg potencies are also available in bottles of 1000 tablets. (J3-527D)

References: 1. Epstein M, Oster JR: Beta-blockers and the kidney. *Min Electrolyte Metab* 8:237-254, 1982. 2. Danesh BJ, et al: Comparison between short-term renal haemodynamic effects of propranolol and nadolol in essential hypertension: a cross-over study. *Clin Sci* 67:243-248, 1984. 3. Hollenberg NK: Introduction: Beta-adrenergic blocking agents—the treatment of hypertension and the kidney. *Royal Soc of Med Int Congress and Symposium Series* 51:1-8, 1982. 4. Frohlich ED, et al: Long-term renal hemodynamic effects of nadolol in patients with essential hypertension. *Am Heart J* 108:1141-1143, 1984. 5. Alexander JC, et al: Long-term experience with nadolol in treatment of hypertension and angina pectoris. *Am Heart J* 108:1136-1140, 1984.



SQUIBB



Innovators in cardiovascular medicine

*Since with increasing blood pressure
there may be a progressive decline
in renal blood flow,¹
prescribe . . .*

CORGARD[®] (nadolol
tablets)

**Lowers
blood pressure**

**Preserves
renal blood flow**



*Studies prove that CORGARD
(nadolol tablets) preserves renal
blood flow unlike some beta-
blockers, such as propranolol.¹⁻⁴*

*In a two-year study of 106 patients,
CORGARD also decreased serum
creatinine, a measurement of
improved renal function.⁵*

- Offers once-a-day convenience.
- Low incidence of CNS side effects.*
- Avoids potassium depletion.
- Maintains long-term control.

CORGARD[®]
(nadolol tablets)

**STEP-1
FOR HYPERTENSION
WITH ONCE-A-DAY DOSE**

*For a discussion of CONTRAINDICATIONS,
PRECAUTIONS, ADVERSE REACTIONS, and
WARNINGS, including avoidance of abrupt
withdrawal, please see brief summary of prescribing
information on adjacent page.



NEW: 300 mg tablets



Not surprising

ZANTAC[®]
(ranitidine HCl/Glaxo)
is rapidly emerging
as the
standard in
its class.

Zantac[®]
ranitidine HCl/Glaxo


300 mg tablets
150 mg tablets
25 mg/ml vials, 2 ml, 10 ml

Glaxo / **ROCHE**


ZAN 287

In 7 of 10
anxious
geriatrics...

Anxiety and
depressive
symptoms
go hand
in hand.



Xanax effectively relieves anxiety with associated depressive symptoms.



In a recent clinical study¹ of 83 geriatric patients with clinical anxiety, 73% were diagnosed as having symptoms of depressed mood.

XANAX is well suited for therapy because it demonstrates greater efficacy than does placebo in reducing the Hamilton Anxiety Rating Scale Total Score and individual items, including depressed mood (see Figure).


With clinical advantages for geriatric patients.

- Effectively relieves the symptoms of anxiety
- Also relieves anxiety with associated depressed mood
- Well tolerated—side effects, if they occur, are generally observed at the beginning of therapy and usually disappear with continued medication. Drowsiness and light-headedness were the most commonly reported adverse reactions
- Does not cause cardiovascular toxicity
- **Specific geriatric dosage**—0.25 mg, two or three times daily

1. Cohn JB: Double-blind safety and efficacy comparison of alprazolam and placebo in the treatment of anxiety in geriatric patients *Curr Ther Res* 1984;35(1):100-112.



Xanax[®] 0.25 mg
Tablets
alprazolam[®] IV



The Endangered Species?

They look happy, healthy and vigorous. The all-American family. But are they as healthy as they look, or will they become the endangered species?

The solvents, thinners and chemicals at his job are far more harmful than he realizes. The herbicides and pesticides that contaminate their food are just as hazardous. The DDT and PCBs that have been found in the fresh fish she serves are a dangerous addition to their diet.

The environmental toxins they encounter every day of their lives makes them prime candidates for serious health problems—from infertility, to neurologic disorders, to cancer. Now you can discover whether your patients' vague, nonspecific symptoms such as fatigue, headache, loss of memory are the result of exposure to toxic substances. Male sterility, immune suppression, peripheral neuropathy, organic brain syndromes, hepatitis and other diseases have been linked to exposure to toxins.

Pacific Toxicology Laboratories is the first and only clinical diagnostic laboratory in the Western United States specializing in testing human samples—blood, urine, adipose tissue—for 33 different environmental toxins.

We provide you with screening tests for volatile solvents, PCBs, organochlorine pesticides such as DDT, and other hazardous substances. We deliver the results in 48 to 72 hours. Our staff of M.D. and Ph.D. toxicologists and clinical chemists give you a detailed analysis and interpretation of our findings.

Pacific Toxicology Laboratories supplies the glassware and instructions necessary for collecting and shipping samples. For information and materials call toll-free (800) 23-TOXIC in California, (800) 32-TOXIC outside California, or (213) 479-4911 in the Los Angeles area.

Yes, please send me more information about the "Endangered Species" screening tests.

PHYSICIAN'S NAME

ADDRESS

CITY

STATE

TELEPHONE



PACIFIC TOXICOLOGY LABORATORIES

1545 BONTIUS AVENUE, LOS ANGELES, CA 90025 (213) 479-4911

The Only Microencapsulated KCl Delivery System Now Delivers Both 8mEq K & 10mEq K



MICRO-K[®]

(Potassium Chloride)

Controlled-Release Extencaps[®] 600 mg (8 mEq K)

MICRO-K 10[®]

(Potassium Chloride)

Controlled-Release Extencaps[®] 750 mg (10 mEq K)

A-H-ROBINS

Pharmaceutical Division, Richmond, Virginia 23261-6609

Member of Certified Medical Representatives Institute

©A.H. Robins Company 1984

BALANCED CALCIUM CHANNEL BLOCKER



CARDIZEM
(diltiazem HCl)

balances
potent
coronary
vasodilation
with a low
incidence of
side effects

Low incidence of side effects
CARDIZEM® (diltiazem HCl) produces an incidence of adverse reactions not greater than that reported with placebo therapy, thus contributing to the patient's sense of well-being.

Indicated in the treatment of angina pectoris due to coronary artery disease and in the management of chronic stable angina (including variant angina) in patients who cannot tolerate other antianginal drugs or who remain symptomatic on adequate doses of these agents.

See package insert for complete list of safety and efficacy information. For complete prescribing information, see package insert for **CARDIZEM** (diltiazem HCl) tablets and capsules. *Am J Cardiol* 53:100-101 (1984).

See package insert for complete list of safety and efficacy information. For complete prescribing information, see package insert for **CARDIZEM** (diltiazem HCl) tablets and capsules. *Am J Cardiol* 53:100-101 (1984).

Reduces angina attack frequency*
42% to 46% decrease reported in multicenter study.¹

Increases exercise tolerance*
In Bruce exercise test,² control patients averaged 8.0 minutes to onset of pain; Cardizem patients averaged 9.8 minutes ($P < .005$).

CARDIZEM®
(diltiazem HCl)

**THE BALANCED
CALCIUM CHANNEL BLOCKER**


Please see full prescribing information on following page.

PROFESSIONAL USE INFORMATION



DESCRIPTION

CARDIZEM® (diltiazem hydrochloride) is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). Chemically, diltiazem hydrochloride is 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (+)-cis-. The chemical structure is:



Diltiazem hydrochloride is a white to off-white crystalline powder with a bitter taste. It is soluble in water, methanol, and chloroform. It has a molecular weight of 450.98. Each tablet of CARDIZEM contains either 30 mg or 60 mg diltiazem hydrochloride for oral administration.

CLINICAL PHARMACOLOGY

The therapeutic benefits achieved with CARDIZEM are believed to be related to its ability to inhibit the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle.

Mechanisms of Action. Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways:

1. **Angina Due to Coronary Artery Spasm:** CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasm are inhibited by CARDIZEM.
2. **Exertional Angina:** CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal exercise work loads.

In animal models, diltiazem interferes with the slow inward (depolarizing) current in excitable tissue. It causes excitation-contraction uncoupling in various myocardial tissues without changes in the configuration of the action potential. Diltiazem produces relaxation of coronary vascular smooth muscle and dilation of both large and small coronary arteries at drug levels which cause little or no negative inotropic effect. The resultant increases in coronary blood flow (epicardial and subendocardial) occur in ischemic and nonischemic models and are accompanied by dose-dependent decreases in systemic blood pressure and decreases in peripheral resistance.

Hemodynamic and Electrophysiologic Effects. Like other calcium antagonists, diltiazem decreases sinoatrial and atrioventricular conduction in isolated tissues and has a negative inotropic effect in isolated preparations. In the intact animal, prolongation of the AH interval can be seen at higher doses.

In man, diltiazem prevents spontaneous and ergonovine-provoked coronary artery spasm. It causes a decrease in peripheral vascular resistance and a modest fall in blood pressure and, in exercise tolerance studies in patients with ischemic heart disease, reduces the heart rate-blood pressure product for any given work load. Studies to date, primarily in patients with good ventricular function, have not revealed evidence of a negative inotropic effect; cardiac output, ejection fraction, and left ventricular end diastolic pressure have not been affected. There are as yet few data on the interaction of diltiazem and beta-blockers. Resting heart rate is usually unchanged or slightly reduced by diltiazem.

Intravenous diltiazem in doses of 20 mg prolongs AH conduction time and AV node functional and effective refractory periods approximately 20%. In a study involving single oral doses of 300 mg of CARDIZEM in six normal volunteers, the average maximum PR prolongation was 14% with no instances of greater than first-degree AV block. Diltiazem-associated prolongation of the AH interval is not more pronounced in patients with first-degree heart block. In patients with sick sinus syndrome, diltiazem significantly prolongs sinus cycle length (up to 50% in some cases).

Chronic oral administration of CARDIZEM in doses of up to 240 mg/day has resulted in small increases in PR interval, but has not usually produced abnormal prolongation. There were, however, three instances of second-degree AV block and one instance of third-degree AV block in a group of 959 chronically treated patients.

Pharmacokinetics and Metabolism. Diltiazem is absorbed from the tablet formulation to about 80% of a reference capsule and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%. CARDIZEM undergoes extensive hepatic metabolism in which 2% to 4% of the unchanged drug appears in the urine. In vitro binding studies show CARDIZEM is 70% to 80% bound to plasma proteins. Competitive ligand binding studies have also shown CARDIZEM binding is not altered by therapeutic concentrations of digoxin, hydrochlorothiazide, phenylbutazone, propranolol, salicylic acid, or warfarin. Single oral doses of 30 to 120 mg of CARDIZEM result in detectable plasma levels within 30 to 60 minutes and peak plasma levels two to three hours after drug administration. The plasma elimination half-life following single or multiple drug administration is approximately 3.5 hours. Desacetyl diltiazem is also present in the plasma at levels of 10% to 20% of the parent drug and is 25% to 50% as potent a coronary vasodilator as diltiazem. Therapeutic blood levels of CARDIZEM appear to be in the range of 50 to 200 ng/ml. There is a departure from dose-linearity when single doses above 60 mg are given; a 120-mg dose gave blood levels three times that of the 60-mg dose. There is no information about the effect of renal or hepatic impairment on excretion or metabolism of diltiazem.

INDICATIONS AND USAGE

1. **Angina Pectoris Due to Coronary Artery Spasm.** CARDIZEM

is indicated in the treatment of angina pectoris due to coronary artery spasm. CARDIZEM has been shown effective in the treatment of spontaneous coronary artery spasm presenting as Prinzmetal's variant angina (resting angina with ST-segment elevation occurring during attacks).

2. **Chronic Stable Angina (Classic Effort-Associated Angina).** CARDIZEM is indicated in the management of chronic stable angina. CARDIZEM has been effective in controlled trials in reducing angina frequency and increasing exercise tolerance. There are no controlled studies of the effectiveness of the concomitant use of diltiazem and beta-blockers or of the safety of this combination in patients with impaired ventricular function or conduction abnormalities.

CONTRAINDICATIONS

CARDIZEM is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker, and (3) patients with hypotension (less than 90 mm Hg systolic).

WARNINGS

1. **Cardiac Conduction.** CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (six of 1243 patients for 0.48%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem.
2. **Congestive Heart Failure.** Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients.
3. **Hypotension.** Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.
4. **Acute Hepatic Injury.** In rare instances, patients receiving CARDIZEM have exhibited reversible acute hepatic injury as evidenced by moderate to extreme elevations of liver enzymes. (See PRECAUTIONS and ADVERSE REACTIONS.)

PRECAUTIONS

General. CARDIZEM (diltiazem hydrochloride) is extensively metabolized by the liver and excreted by the kidneys and in bile. As with any new drug given over prolonged periods, laboratory parameters should be monitored at regular intervals. The drug should be used with caution in patients with impaired renal or hepatic function. In subacute and chronic dog and rat studies designed to produce toxicity, high doses of diltiazem were associated with hepatic damage. In special subacute hepatic studies, oral doses of 125 mg/kg and higher in rats were associated with histological changes in the liver which were reversible when the drug was discontinued. In dogs, doses of 20 mg/kg were also associated with hepatic changes; however, these changes were reversible with continued dosing.

Drug Interaction. Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM. (See WARNINGS.)

Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers or digitalis is usually well tolerated. Available data are not sufficient, however, to predict the effects of concomitant treatment, particularly in patients with left ventricular dysfunction or cardiac conduction abnormalities. In healthy volunteers, diltiazem has been shown to increase serum digoxin levels up to 20%.

Carcinogenesis, Mutagenesis, Impairment of Fertility. A 24-month study in rats and a 21-month study in mice showed no evidence of carcinogenicity. There was also no mutagenic response in *in vitro* bacterial tests. No intrinsic effect on fertility was observed in rats.

Pregnancy. Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from five to ten times greater (on a mg/kg basis) than the daily recommended therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities. In the perinatal/postnatal studies, there was some reduction in early individual pup weights and survival rates. There was an increased incidence of stillbirths at doses of 20 times the human dose or greater.

There are no well-controlled studies in pregnant women; therefore, use CARDIZEM in pregnant women only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when CARDIZEM is administered to a nursing woman if the drug's benefits are thought to outweigh its potential risks in this situation.

Pediatric Use. Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded.

In domestic placebo-controlled trials, the incidence of adverse reactions reported during CARDIZEM therapy was not greater than that reported during placebo therapy.

The following represent occurrences observed in clinical studies which can be at least reasonably associated with the pharmacology of calcium influx inhibition. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences, as well as their frequency of presentation, are: edema (2.4%),

headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), asthenia (1.2%), AV block (1.1%). In addition, the following events were reported infrequently (less than 1%) with the order of presentation corresponding to the relative frequency of occurrence.

Cardiovascular:	Flushing, arrhythmia, hypotension, bradycardia, palpitations, congestive heart failure, syncope.
Nervous System:	Paresthesia, nervousness, somnolence, tremor, insomnia, hallucinations, and amnesia.
Gastrointestinal:	Constipation, dyspepsia, diarrhea, vomiting, mild elevations of alkaline phosphatase, SGOT, SGPT, and LDH.
Dermatologic:	Pruritus, petechiae, urticaria, photosensitivity.
Other:	Polyuria, nocturia.

The following additional experiences have been noted:

A patient with Prinzmetal's angina experiencing episodes of vasospastic angina developed periods of transient asymptomatic asystole approximately five hours after receiving a single 60-mg dose of CARDIZEM.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: erythema multiforme; leukopenia; and extreme elevations of alkaline phosphatase, SGOT, SGPT, LDH, and CPK. However, a definitive cause and effect between these events and CARDIZEM therapy is yet to be established.

OVERDOSAGE OR EXAGGERATED RESPONSE

Overdosage experience with oral diltiazem has been limited. Single oral doses of 300 mg of CARDIZEM have been well tolerated by healthy volunteers. In the event of overdosage or exaggerated response, appropriate supportive measures should be employed in addition to gastric lavage. The following measures may be considered:

Bradycardia	Administer atropine (0.60 to 1.0 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.
High-Degree AV Block	Treat as for bradycardia above. Fixed high-degree AV block should be treated with cardiac pacing.
Cardiac Failure	Administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics.
Hypotension	Vasopressors (eg, dopamine or levarterenol bitartrate).

Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician.

The oral LD₅₀'s in mice and rats range from 415 to 740 mg/kg and from 560 to 810 mg/kg, respectively. The intravenous LD₅₀'s in these species were 60 and 38 mg/kg, respectively. The oral LD₅₀ in dogs is considered to be in excess of 50 mg/kg, while lethality was seen in monkeys at 360 mg/kg. The toxic dose in man is not known, but blood levels in excess of 800 ng/ml have not been associated with toxicity.

DOSEAGE AND ADMINISTRATION

Exertional Angina Pectoris Due to Atherosclerotic Coronary Artery Disease or Angina Pectoris at Rest Due to Coronary Artery Spasm. Dosage must be adjusted to each patient's needs. Starting with 30 mg four times daily, before meals and at bedtime, dosage should be increased gradually (given in divided doses three or four times daily) at one- to two-day intervals until optimum response is obtained. Although individual patients may respond to any dosage level, the average optimum dosage range appears to be 180 to 240 mg/day. There are no available data concerning dosage requirements in patients with impaired renal or hepatic function. If the drug must be used in such patients, titration should be carried out with particular caution.

Concomitant Use With Other Antianginal Agents:

1. **Sublingual NTG** may be taken as required to abort acute anginal attacks during CARDIZEM therapy.
2. **Prophylactic Nitrate Therapy**—CARDIZEM may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
3. **Beta-blockers.** (See WARNINGS and PRECAUTIONS.)

HOW SUPPLIED

Cardizem 30-mg tablets are supplied in bottles of 100 (NDC 0088-1771-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1771-49). Each green tablet is engraved with MARION on one side and 1771 engraved on the other. CARDIZEM 60-mg scored tablets are supplied in bottles of 100 (NDC 0088-1772-47) and in Unit Dose Identification Paks of 100 (NDC 0088-1772-49). Each yellow tablet is engraved with MARION on one side and 1772 on the other.

Issued 4/1/84

Another patient benefit product from



*"When that summons came,
I was glad I had SCPIE.*

*"My reputation was on the line,
but SCPIE had the right people
to handle everything.*

*"They know how to protect
a physician."*

Experience and strong physician
management help make SCPIE
Number One.


SCPIE is the largest Medical
Association/Society-sponsored,
physician-owned writer of claims
made professional liability insur-
ance in the nation!

This means:

Rates at the lowest possible level
consistent with a stable company.
The physician gets back premium
dollars, plus investment income, not
needed to pay claims and costs.

Already insured?

Ask about SCPIE's nose coverage. It
lets qualified physicians move from
another claims made carrier without
paying "tail" coverage to the prior
company. You join SCPIE at a pre-
mium commensurate with your rate
and years of coverage under the
prior plan.




scpie

Southern California
Physicians Insurance
Exchange

2029 Century Park East
Suite 2300
Los Angeles, CA 90067
(213) 552-8900

The cure for terminal anxiety.



Unlike most terminal cases, there is a cure for medical computer terminal anxiety: WESTLAND SOFTWARE.

With the wave of a wand, the bar code reader brings files to your fingertips. It's faster and eliminates keyboard errors that are made with other systems.


We've specialized in nothing but medical systems for more than a decade. Using reliable Hewlett-Packard equipment, our system

was developed, tested and proven in offices just like yours. With our system,

you instantly have access to medical records, insurance forms, appointment schedules, you name it.

With WESTLAND, the conversion is painless. We provide the most complete installation service including customer training, key-punching of your information and ongoing customer support. And since your new system will be tailored to meet your special needs, you will see the very best results.

Now that you know there's a cure for your terminal anxiety, why wait any longer? Call for your demonstration today.



Westland Medical Systems

20847 Sherman Way, Suite 300 Canoga Park, CA 91306
In California 818/992-0081 In California 800/468-9358

Name _____

Address _____

City _____ State _____ Zip _____

Phone (____) _____

WESTLAND MEDICAL SYSTEMS

In California, Theo-Dur is
the only oral theophylline
that delivers an essentially
equal dose every hour.

But only if you say so.

R_x


Dispense
as written

The only zero-order oral theophylline.

THEO-DUR[®]
(theophylline anhydrous) Sustained
Action
Tablets

Please see next page for brief summary of prescribing information.

Easy To Take



Keflex[®]
cephalexin

Additional information
available to the profession
on request.



420113

Dista Products Company
Division of Eli Lilly and Company
Indianapolis, Indiana 46285
Mfd. by Eli Lilly Industries, Inc.
Carolina, Puerto Rico 00630

THE LANCET

ORIGINAL ARTICLES

The Lancet • Saturday 15 June 1985

MORTALITY AND MORBIDITY RESULTS FROM THE EUROPEAN WORKING PARTY ON HIGH BLOOD PRESSURE IN THE ELDERLY TRIAL¹

Results:
38% reduction in
cardiac deaths
confirms effectiveness
of antihypertensive
treatment²
Antihypertensive*
Used³:

DYAZIDE®

25 mg Hydrochlorothiazide/80 mg Triamterene/SKF

1. A long-term, double-blind, randomized, placebo-controlled trial of antihypertensive treatment in 840 patients over age 60.
2. Results of an intention-to-treat analysis combining the double-blind part of the trial and all subsequent follow-up. The overall mortality rate was not significantly reduced.
3. At first, all patients received one 'Dyazide' daily or placebo. The dosage could be increased after two weeks to two capsules per day. After one month, if necessary, methylglucamine tablets could be added to the active treatment group and placebo tablets to the placebo group.

Before prescribing, see complete prescribing information in SK&F CO. literature or PDR. The following is a brief summary.

WARNING

This drug is not indicated for initial therapy of edema or hypertension. Edema or hypertension requires therapy titrated to the individual. If this combination represents the dosage so determined, its use may be more convenient in patient management. Treatment of hypertension and edema is not static, but must be reevaluated as conditions in each patient warrant.

Contraindications: Concomitant use with other potassium-sparing agents such as spironolactone or amiloride. Further use in anuria, progressive renal or hepatic dysfunction, hyperkalemia. Pre-existing elevated serum potassium. Hypersensitivity to either component or other sulfonamide-derived drugs.

Warnings: Do not use potassium supplements, dietary or otherwise, unless hypokalemia develops or dietary intake of potassium is markedly impaired. If supplementary potassium is needed, potassium tablets should not be used. Hyperkalemia can occur, and has been associated with cardiac irregularities. It is more likely in the severely ill, with urine volume less than one liter/day, the elderly and diabetics with suspected or confirmed renal insufficiency. Periodically, serum K⁺ levels should be determined. If hyperkalemia develops, substitute a thiazide alone, restrict K⁺ intake. Associated widened QRS complex or arrhythmia requires prompt additional therapy. Thiazides cross the placental barrier and appear in cord blood. Use in pregnancy requires weighing anticipated benefits against possible hazards, including fetal or neonatal jaundice, thrombocytopenia, other adverse reactions seen in adults. Thiazides appear and triamterene may appear in breast milk. If their use is essential, the patient should stop nursing. Adequate information on use in children is not available. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus has been reported with thiazide diuretics.

Precautions: The bioavailability of the hydrochlorothiazide component of 'Dyazide' is about 50% of the bioavailability of the single entity. Theoretically, a patient transferred from the single entities of Dyrenium (triamterene, SK&F CO.) and hydrochlorothiazide may show an increase in blood pressure or fluid retention. Similarly, it is also possible that the lesser hydrochlorothiazide bioavailability could lead to increased serum potassium levels. However, extensive clinical experience with 'Dyazide' suggests that these conditions have not been commonly observed in clinical practice. Do periodic serum electrolyte determinations (particularly important in patients vomiting excessively or receiving parenteral fluids, and during concurrent use with amphotericin B or corticosteroids or corticotropin [ACTH]). Periodic BUN and serum creatinine determinations should be made, especially in the elderly, diabetics or those with suspected or confirmed renal insufficiency. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate coma in patients with severe liver disease. Observe regularly for possible blood dyscrasias, liver damage, other idiosyncratic reactions. Blood dyscrasias have been reported in patients receiving triamterene, and leukopenia, thrombocytopenia, agranulocytosis, and aplastic and hemolytic anemia have been reported with thiazides. Thiazides may cause manifestation of latent diabetes mellitus. The effects of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary. Clinically insignificant reductions in arterial responsiveness to norepinephrine have been reported. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine. Triamterene is a weak folic acid antagonist. Do periodic blood studies in cirrhotics with splenomegaly. Antihypertensive effects may be enhanced in post-sympathectomy patients. Use cautiously in surgical patients. Triamterene has been found in renal stones in association with the other usual calculus components. Therefore, 'Dyazide' should be used with caution in patients with histories of stone formation. A few occurrences of acute renal failure have been reported in patients on 'Dyazide' when treated with indomethacin. Therefore, caution is advised in administering nonsteroidal anti-inflammatory agents with 'Dyazide'. The following may occur: transient elevated BUN or creatinine or both, hyperglycemia and glycosuria (diabetic insulin requirements may be altered), hyperuricemia and gout, digitalis intoxication (in hypokalemia), decreasing alkali reserve with possible metabolic acidosis. 'Dyazide' interferes with fluorescent measurement of quinidine. Hypokalemia is uncommon with 'Dyazide', but should it develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods. Corrective measures should be instituted cautiously and serum potassium levels determined. Discontinue corrective measures and 'Dyazide' should laboratory values reveal elevated serum potassium. Chloride deficit may occur as well as dilutional hyponatremia. Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Serum PBI levels may decrease without signs of thyroid disturbance. Calcium excretion is decreased by thiazides. 'Dyazide' should be withdrawn before conducting tests for parathyroid function.

Thiazides may add to or potentiate the action of other antihypertensive drugs. Diuretics reduce renal clearance of lithium and increase the risk of lithium toxicity.

Adverse Reactions: Muscle cramps, weakness, dizziness, headache, dry mouth; anaphylaxis, rash, urticaria, photosensitivity, purpura, other dermatological conditions; nausea and vomiting, diarrhea, constipation, other gastrointestinal disturbances; postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Necrotizing vasculitis, paresthesias, icterus, pancreatitis, xanthopsia and respiratory distress including pneumonitis and pulmonary edema, transient blurred vision, sialadenitis, and vertigo have occurred with thiazides alone. Triamterene has been found in renal stones in association with other usual calculus components. Rare incidents of acute interstitial nephritis have been reported. Impotence has been reported in a few patients on 'Dyazide', although a causal relationship has not been established.

Supplied: 'Dyazide' is supplied as a red and white capsule, in bottles of 1000 capsules; Single Unit Packages (unit-dose) of 100 (intended for institutional use only); in Patient-Pak™ unit-of-use bottles of 100.

BRS-DZ-L41

a product of

SK&F CO.

Carolina, P.R. 00630

© SK&F Co., 1985

The unique red and white Dyazide® capsule: Your assurance of SK&F quality.





To us, there's no difference between Trust and trust.

One of the purposes of a trust is to protect your family's assets.

So it makes sense to invest with an institution you can trust—one with remarkable resources and a formidable track record.

On those two counts, First Interstate Bank is clearly superior.

Our friendly Trust Services experts are knowledgeable in all kinds of trusts. So they'll take the time to understand your needs and develop an investment

program to fit your family's objectives.

They also have guided clients to highly profitable investments. Their investment performance has consistently been superior in both equity and fixed income markets.

In addition, by selecting First Interstate Bank, you tap the resources of a bank with over \$5.6 billion in assets and offices all across Arizona.

So if you want your trust plan backed by that kind of strength, call

First Interstate's Trust office at 271-6595. You can trust us with your assets just as your family trusts you to provide for them.



FIRST INTERSTATE BANK OF ARIZONA, N.A.
Member FDIC • Federal Reserve System
Equal Opportunity Employer

MICA
"A"
(Excellent)

rated by A. M. Best Co.

continues to provide

**Medical Malpractice
Insurance**

**to the preferred
Arizona Physicians
in 1986 as
we have since 1976.**

For more facts, please call the MICA Underwriting
Department (602) 271-4019
or toll free (800) 352-0402

MICA MICA MICA

MUTUAL INSURANCE COMPANY OF ARIZONA Sponsored by: **Arizona Medical Association**
Arizona Osteopathic Medical Association

Announcing...

THE LINCOLN URODIAGNOSTIC CENTER


**A comprehensive approach
to urologic disorders.**

**The Lincoln Urodiagnostic Center
provides screening, diagnosis,
education and treatment for a
variety of genitourinary problems.**


These include:

- **IMPOTENCE**
- **INCONTINENCE**
- **STONES**
- **OBSTRUCTION**
- **INFERTILITY**
- **INFLAMMATION**

**Services are provided
in a comfortable,
cost-conscious
outpatient setting
on the campus of
John C. Lincoln
Hospital & Health
Center in north
central Phoenix.**



DIRECTORS
Raymond A. Hurm, M.D.
James H. Suess, M.D.
COORDINATOR
Bonnie Cornille, B.S., R.N.



**LINCOLN
URODIAGNOSTIC
CENTER**™ pending

Affiliated with Lincoln Health Resources

**North Phoenix Medical Center
9200 North 3rd Street, Suite 24
Phoenix, Arizona 85020-2495
602-943-2800**

Putting good health within easy reach!



“He flourished during the first half of the 20th century.”

The American physician isn't extinct. But your freedom to practice is endangered. Increasing government intervention is threatening the quality of medicine — and your right to function as an independent professional. The government, responding to cost containment pressures from myriad sources, has taken a more active role in legislating reimbursement methods, payment levels and even access to care.

In your fight for survival, the American Medical Association is your best weapon. The AMA is the most influential force in health care. No other organization can so effectively reach the national policymakers who will help determine your future and the future of medicine.

Join the AMA. We're your voice in Washington. And we're fighting for you — and your patients.

For more information, call the AMA collect (312) 645-4783, or return this coupon to your state or county society.

The American Medical Association



535 North Dearborn, Chicago, Illinois 60610

Please send me membership information.

Name

Address

City State Zip

County ☐ Member, County Medical Society



ARIZONA MEDICAL ASSOCIATION

**LIFE, DISABILITY, ACCIDENT
BUSINESS OVERHEAD
INSURANCE**

**Call
1-(800)-556-0800**



administered by

HEALTH AGENCIES OF THE WEST, INC.

P.O. Box 3708, Tustin, California 92681-3708

local service by

ARIZONA MEDICAL ASSOCIATION, INC.

1-(800)-482-3480 —or— 246-8901 for the Phoenix area

Classified Advertising

We Bind Your PERIODICALS

Preserve your medical journals as beautifully bound books. Choose from 30 different colors of durable Library Buckram.

\$14.50 per volume, (name imprint \$1.00)

\$15.50 Imitation Leather, (rules .50 each)

Inquire about quantity discounts. **Free** local pickup and delivery on 10 volumes or more. Minimum order is \$25.00.

ROSWELL BOOKBINDING

2614 North 29th Avenue

Phoenix, Arizona 85009 ■ (602) 272-9338



**WE COVER YOUR
MEDICAL EQUIPMENT
NEEDS**

- Preventive Maintenance
- Demand Repair
- Equipment Planning and Control
- Radiology (including Q.A.) –
Anesthesiology – Respiratory –
Cardiac Monitoring Equipment
and More.

*"We Shape Technology for the
Health Care Industry"*

ENTECH

4401 South 36th Street
Phoenix, Arizona 85040
(602) 437-9081

Pain Control T.E.N.S. Units & Other Hi-Tech Medical Equipment

Non-Invasive, no drug interaction
Can help reduce insurance premiums

Rental, Leasing, or Purchase

Eaton Medical Systems

800-821-1989 x485

602-944-5047

YOU WORKED HARD



**FOR THAT
DIPLOMA...**

**why not have it
laminated?**

It will last a lifetime....

THE PLAQUE SHOP

Wood plaques — Ready to hang
No glass to break — Moisture proof
Dirt proof — Impressive.
Our plaques are manufactured locally.

ARIZONA LAMINATING SERVICE, INC.

7231 East First Avenue
Scottsdale, Arizona 85251
(602) 945-9338

DANNY T. SEIVERT INSURANCE, INC.

Professional Programs
for Professional People

70 E. Mitchell Dr., Suite 6
Phoenix, Arizona 85012
263-9090

PROFESSIONAL OPPORTUNITIES

INTERNIST

To do primary care in multi-specialty clinic. Full in-house lab and x-ray. Office adjacent to hospital. Delightful community. Good schools and recreation. Reply to: P.O. Box 0955, C/O Arizona Medicine, 810 West Bethany Home Road, Phoenix, Arizona 85013.

PHOENIX, ARIZONA; FAMILY PRACTICE PHYSICIANS

A board certified/eligible Physician is needed for a busy, established Hispanic family medicine practice. There is also an excellent private practice opportunity for a board certified Family Practitioner. If interested in either position, submit confidential CV to: Clarke & Associates, P.O. Box 17138, Phoenix, AZ 85011, (602) 266-7005.

INTERNAL MEDICINE

Internal Medicine Practice with considerable Rheumatology located in Arizona. Attractive well-equipped practice. Send CV to: Health Care Personnel Consulting, Inc., 400 GSB Building, One Belmont Avenue, Bala Cynwyd, Pennsylvania 19004, or call: (215)667-8630.

MEDICAL OFFICES

FOR SALE OR LEASE

Office in Tucson Medical Center Medical Park. 1900 square feet. Accommodates 1-3 doctors. Fully upgraded and professionally decorated. Call (602) 325-2512 for an appointment to see.

MEDICAL BUILDING FOR LEASE

3,000 square feet, 3417 North 32nd Street, Phoenix, Arizona. Includes lab, x-ray, physical therapy or surgery. Ideal for 1-3 physicians. (602)956-5031 or 956-0959.

MOON VALLEY:

Wanted: M.D.s — general and specialty — as **equity partners** in new professional building now planning. Fast-growing area currently without M.D. services. 19th Avenue and Thunderbird. G.M. Steen, (602) 863-2186.

REAL ESTATE

2 FOUR PLEX APARTMENTS

Side by side with 20-foot drive between. Excellent area 5 minutes from center of business district. Each apartment approximately 900 square feet living. One-year-old, both fully rented. Hidden by mature trees from street. Will sell one or both together. The price is \$179,900 each. Owner agent. (602) 837-1195.

HOME FOR SALE

Magnificent Georgian Estate. North Scottsdale. One acre. Four or five bedrooms. Hardwood floors, library — solid wood built-ins. Second level perfect for teens or guests. Heated pool and spa. Brick patios, gazebo. All amenities plus 24-hour gatehouse security. Priced below appraisal at \$425,000. Realty Consultants. Pat. (602) 948-5637.

MISCELLANEOUS

THE COMMUNICATION LINK YOU NEED

To present medical information in an understandable manner. Patient brochures, newsletters, speeches, feature articles, biographies, public relations packets, educational programs, even ghostwriting. Call to arrange a time to discuss your needs. Dependable — Experienced — Flexible. Dorothy Tegeler (602) 863-4362.

LARGE LOANS

Since 1966 specializing in large loans to physicians nationwide from \$15,000.00 to \$90,000.00. Long repayment terms at fixed interest rates. Commitments usually within 48 hours. Woodside Capital Corp., Woodside Capital Building, P.O. Box 368, Woodland Hills, CA 91365. For further information call (800) 423-5025.

\$1,250 WEEKLY HOME-MAILING PROGRAM!

Guaranteed earnings. Start immediately. **Free details.** Rush stamped, self-addressed envelope to: S & B Publications, 804 Old Thorsby Road, Clanton, Alabama 35045.

BIOMEDICAL ENGINEERING SERVICES

Covering all aspects of medical instrumentation—diagnostic and therapeutic—Quality assurance—repair and calibrations—safety checks to meet state code requirements—sale of completely overhauled and guaranteed used equipment. Prompt, courteous service. Modest rates. 3901 West Sharon Avenue, Phoenix, Arizona. (602) 978-9157.

PHYSICIANS SIGNATURE LOANS


Loans to \$50,000. Competitive fixed rates, with no points, fees or charges of any kind. No collateral. Up to six years to repay with no pre-payment penalties. Prompt, courteous service. Physicians Service Association, Atlanta, Georgia (800) 241-6905. Serving MDs for over ten years.

1986 CME CRUISE/CONFERENCES

On selected medical topics. Caribbean, Mexican, Hawaiian, Alaskan, Mediterranean. 7 - 12 days year-round. Approved for 20 - 24 CME category 1 credits. (AMA/PRA) & AAFP prescribed credits. Distinguished professors. **Fly roundtrip free on Caribbean, Mexican, Mediterranean, Alaskan cruises.** Excellent group fares on finest ships. Registration limited. Pre-scheduled in compliance with present IRS requirements. Information: International Conferences, 189 Lodge Avenue, Huntington Station, N.Y. 11746. (516) 549-0869.

Classified ad rates are \$20 for the first 50 words or less and 20 cents for each additional word. Send to: ArMA, 810 West Bethany Home Road, Phoenix, Arizona 85013.

American
College of
Physicians
presents...



Gateway to a Golden Medical Opportunity

67th ANNUAL SESSION
APRIL 10-13, 1986
MOSCONE CENTER

Join us in San Francisco for Internal Medicine's Premier Meeting!

- Plan your own CME curriculum from over 300 scientific presentations . . . covering 14 major internal medicine subspecialties
- Discuss your problem cases with medicine's leading teachers and clinicians
- Find out how the new science of Medical Informatics can help you now and in the future
- Learn how discoveries in the "New Genetics" are affecting clinical medicine
- Choose from either of two pre-meeting courses on Critical Care or Management of Acute Myocardial Infarction
- Bring your spouse and family to enjoy a full schedule of special activities

**Send for your 1986
Annual Session Scientific Program Guide**

**YES, please mail me the '86
Program Guide**

6W03

NAME _____

ADDRESS _____

CITY _____

STATE _____

ZIP _____

Telephone toll free:
(800) 523-1546

(In Pennsylvania:
(215) 243-1200)

☐ ACP member ☐ non-member

American College of Physicians
4200 Pine Street, Philadelphia, PA 19104

Classified Advertisements

The rate for each insertion is **\$5 per line** (average six words per line) with **five line (\$25) minimum**. Box number charge: \$5 each month.

Classified display rates \$50 per inch.

Copy for classified advertisements should be received not later than **the first of the month preceding issue**. All copy must be typed or printed. • Classified advertisers using Box Numbers forbid the disclosure of their identity. Your inquiries in writing will be forwarded to Box Number advertisers. The right is reserved to reject or modify all classified advertising copy in conformity with the decisions of the Advertising Committee.

Please Type or Print Advertising Copy

Classified Advertisements Are Payable in Advance

THE WESTERN JOURNAL OF MEDICINE
P.O. BOX 7602, SAN FRANCISCO, CA 94120-7602

CALIFORNIA, SAN FRANCISCO BAY AREA: Full-time career Emergency Physician wanted for high volume Emergency Department/Paramedic Base Station. Emergency Medicine Board certified or Board-ready, mandatory to participate in a group of twenty full-time staff physicians seeing over 300 patients per day. Salaried position, excellent benefits include three weeks paid vacation; one week CME; paid malpractice, health and life insurance; corporate shareholding in three years. Send CV or contact David Gallagher, MD, 27400 Hesperian Blvd., Hayward, CA 94545.

PATHOLOGIST—Assistant Director/Pathologist position open in fully-equipped modern 106 bed hospital. Income guarantee. Family-oriented community of Clovis, New Mexico. For additional information, submit CV to: Bill Norris, Southwest Community Health Services, PO Box 26666, Albuquerque, NM 87125-6666.

INTERNAL MEDICINE—Join an established, lucrative practice located in the prime resort community of Ruidoso, New Mexico. Financial assistance available. Private practice/sharing expenses or possible association. Prefer background in GI. Submit CV to: Bill Norris, Southwest Community Health Services, PO Box 26666, Albuquerque, NM 87125-6666.

GENERAL INTERNIST (BC/BE). United States trained to associate with four young generalists in rapid growth area of central California. Area remains open for establishing a new practice. Near Yosemite and other year-round recreation. Send CV to Dr Cecil Bullard, 5339 N. Fresno St., #107D, Fresno, CA 93710.

OB/GYN: Multispecialty group in Northwest Washington desires second Obstetrician. Excellent practice opportunity, full range of benefits, early partnership status, all practice costs paid. For more information contact Shane Spray, Administration, 1400 E. Kincaid, Mount Vernon, WA 98273; (206) 428-2524.

HEALTH OFFICER for public health district composed of all cities and unincorporated area in Snohomish County, Washington; total population 373,000. MD with MPH required. Competitive compensation plus attractive benefits. Send curriculum vitae to Claris Hyatt, MD, Health Officer, Snohomish Health District, Everett, WA 98201; (206) 259-9383.

OB/GYN—Southern California solo practitioner seeking male/female BE/BC physician to join fast growing practice. Must be dedicated to private care. Fully equipped office. Send CV to Ziyad A. Ghabra, MD, 907 W. Lancaster Blvd., Lancaster, CA 93534.

THORACIC VASCULAR GENERAL SURGEON—To associate with senior Surgeon. Well established referral practice. Salary plus percentage. Central California. Send curriculum vitae to Number 7001, Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

ARIZONA BASED PHYSICIAN RECRUITMENT firm has opportunities Coast to Coast. "Professionals working with Professionals." Over 13 years experience. Call (602) 795-7474; or send CV to: Mitchell & Associates, Inc., 2761 N. Country Club Rd., Ste. 202, Tucson, AZ 85716.

OTOLARYNGOLOGIST position open with 33 member multispecialty group. Board certification or eligibility required. Excellent practice opportunity; full range of benefits, including immediate shareholder status, retirement program, all practice costs paid. For more information contact: Colin Wells, MD, Recruitment Coordinator or David Graham, Associate Administrator, San Luis Medical Clinic, Ltd., 1235 Osos St., San Luis Obispo, CA 93401.

SAN FRANCISCO BAY AREA: Our group has part-time and full-time opportunities available for physicians specializing in family practice, emergency medicine, or internal medicine. Opportunities available at two separate facilities, both located approximately one hour drive from San Francisco. The facilities include an Urgent Care Center offering 12-hour shifts on weekdays or weekends, and a separate contract facility performing employee physical exams weekdays only. Paid malpractice and competitive hourly compensation with small, high quality group. Send CV to the Chase Dennis Group, 873 Corcoran Ct., Benicia, CA 94510.

SOUTH CENTRAL WYOMING—Immediate practice opportunity for Board certified or Board eligible Orthopedic Surgeon and Urologist. Well equipped JCAH hospital. Progressive medical staff of 13 caring for a service area of approximately 20,000 population. No state or city income tax. Relocation incentives. Superior hunting, fishing, camping, snowmobiling. Three hours to Colorado ski area, five hours to Jackson Hole. One and one-half hours to the mountains. If interested, please send CV and references to: T. Goldfarb, MD, Chairman, Recruiting Committee or Richard Mills, Executive Director, Memorial Hospital of Carbon County, Rawlins, WY 82301; (307) 324-2221.

FAMILY PRACTICE-PEDIATRICIAN. Excellent professional opportunity in beautiful north Idaho. For information (208) 784-1221, ext. 304. Shoshone Medical Center, Jacobs Gulch, Kellogg, ID 83837.

WANTED

BAY AREA, multispecialty medical group, looking for Board certified/eligible medical internist. Interested physicians should contact Donald Lass, Administrator at (415) 785-5000 or mail your curriculum vitae to 27212 Calaroga Ave., Hayward, CA 94545.

ASSOCIATE IN PEDIATRICS: Kern Medical Center, Bakersfield, California, a Southern California teaching hospital affiliated with UCLA School of Medicine, seeks an Associate in its Department of Pediatrics. Prerequisites include eligibility or certification by the American Board of Pediatrics, strong interest in child/sexual abuse, teaching and qualifications for faculty appointment in the UCLA Department of Pediatrics. Compensation and benefits are competitive. Please reply with curriculum vitae to Jess Diamond, MD, Chairman, Kern Medical Center Department of Pediatrics, 1830 Flower St., Bakersfield, CA 93305; or telephone (collect) (805) 326-2263.

CARDIOLOGIST, INVASIVE—110-physician, multispecialty, prepaid group located in the San Francisco Bay area wishes to add another Cardiologist/Internist. Practice includes large volume of referrals for invasive procedures. Doppler-echo skills required. University affiliation available. Please contact: E. Andrews Neal, MD, The Permanente Medical Group, Inc., 260 International Circle, San Jose, CA 95119; telephone (collect) (408) 972-3000.

WANTED: Board certified General Internist to join three others in a busy, progressive practice in the Sierra foothills. Beautiful surroundings, but close to urban centers. New facility. Contact Dennis A. Nousaine, MD, FACP, 815 Court St., Ste. 7, Jackson, CA 95642.

INTERNIST, GP OR REHAB MD needed for busy clinic in San Jose, California, in the heart of Silicon Valley. 55 miles from San Francisco. Practice mainly musculoskeletal with concomitant organic related problems. Full- or part-time. Contact Dr Brody, South Bay Health and Fitness Clinic, (408) 947-8088.

OB/GYN, FAMILY PRACTICE, ORTHOPEDIC SURGEON—SEATTLE. OB/GYN opening with medical group. Position also available in Seattle suburb with private practitioner. FP and ORS are hospital sponsored. For details, call Eloise Gusman, 1 (800) 535-7698 or (504) 893-4879. PO Box 1685, Covington, LA 70434-1685.

SOUTHERN CALIFORNIA—Family Practitioner and Cardiologist needed for growing community located between Los Angeles and San Diego. Very attractive area. For details, call Eloise Gusman, 1 (800) 535-7698 or (504) 893-4879. PO Box 1685, Covington, LA 70434-1685.

GYNECOLOGIST—Needed in Ketchum/Sun Valley multispecialty clinic. Excellent climate, unlimited recreation facilities and very good schools. Income dependent on productivity. Dr Bryan Stone, PO Box 2198, Ketchum, ID 83340; (208) 726-9361.

NORTHERN CALIFORNIA, Emergency Medicine—Full-time positions available in the emergency room at The University of California Davis Medical Center. The University serves a large region of Northern California and is a major trauma center. Emergency physicians teach and supervise medical students and house staff in addition to treating patients, primarily. Opportunities exist for involvement in other School of Medicine teaching activities. Applicants should send Curriculum Vitae to Robert W. Derlet, MD, University of California Davis Medical Center, 2315 Stockton Blvd., Department of Emergency Medicine, Trailer 1219, Sacramento, CA 95817.

PATHOLOGIST: Large pathology group in greater Los Angeles area seeking qualified anatomic and clinical Pathologist. Prefer applicants with fellowship training or one to two years experience. Excellent position with growth potential. Send résumé to: Glenview Pathology Medical Group, 9331 Venice Blvd., Culver City, CA 90230; Attn: Dr Emanuel Abrams.

PHYSICIANS WANTED

ASSOCIATE MEDICAL COORDINATOR—California Department of Food and Agriculture has immediate opportunity for physician with graduate training in pharmacology/toxicology. Position will be involved in evaluating potential chemical intoxications and providing medical consultation to agencies and physicians dealing with pesticide chemicals in California; evaluating data submitted to support registration applications for pesticides; making recommendations on regulations necessary to protect health of pesticide workers and the public. Minimum qualifications to be formally adopted by the State Personnel Board: March 1986. Anticipated Exam Date: April 1986. Send résumé to: Department of Food and Agriculture, 1220 N Street, Room 126, Sacramento, CA 95814, by April 11, 1986. Civil Service interview required.

SACRAMENTO—FP/GP/Internist needed March 1 to take over private office and housecalls in association with another physician. Affluent Sacramento suburb. No investment required. Immediate caseload (net \$5,000 + per month). Contact J. Marin, 7415 Winding Way, Fair Oaks, CA 95628; (916) 965-5491.

PULMONOLOGIST/INTERNIST—Wanted, BC or BE pulmonologist to join expanding HMO medical center in Fairfield, California (San Francisco Bay Area). Write to Chief of Department of Medicine, Kaiser-Permanente Medical Center, 1550 Gateway Blvd., Fairfield, CA 94533.

ENT—position available with 35-member multispecialty group on the central coast of California. BC/BE required, excellent practice opportunity; full range of benefits, all practice costs paid, plus immediate shareholder status. Mail CV to: Colin Wells, MD, Recruitment Coordinator, 1235 Osos St., San Luis Obispo, CA 93401. No phone calls please.

INTERNIST—BC/BE, Palmdale-Lancaster, California. Join solo Internist in busy practice of primary care medicine, consultative medicine and critical care medicine. Eventual partnership. Growing community near Los Angeles/mountains/ocean. Send CV to Number 107, Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

EMERGENCY DEPARTMENT PHYSICIAN—Caldwell, Idaho. 150 bed modern hospital, moderate activity. Excellent quality of life and low cost of living. Great weather and proximity to Boise with excellent recreational opportunities. Contact Bob Conrad, Administrator, West Valley Medical Center, 1717 Arlington, Caldwell, ID 83605; (208) 459-4641.

NEUROLOGIST: Position available immediately with small, growth oriented neuro-musculo-rehabilitation clinic. Board certified or eligible. Excellent practice opportunity with all practice costs paid. Superb living conditions on central coast of California. Guaranteed salary with bonus opportunity plus excellent benefit package. Contact and send CV to: David Graham, Administrator, Central Rehabilitation Clinic, Inc., 1334 Marsh St., San Luis Obispo, CA 93401.

BEAUTIFUL WASHINGTON STATE—Family Practitioner sought by group of well-trained Board certified Family Practitioners in a growing and dynamic prepaid health care plan. An unusual opportunity to practice comprehensive family medicine, including obstetrics, where continuity of care, patient education/preventive medicine, and high quality of personal style care are emphasized. We offer the opportunity to practice in Health Care Centers ranging in size from one to eight MDs located in Spokane and outlying communities. Excellent salary and benefits. Spokane is a delightful city containing an exceptionally fine medical community and superb year-round outdoor recreation. Affiliated with Group Health Cooperative of Puget Sound. For further information contact Thomas Kearney, MD, Group Health of Spokane, East 9227 Main, Spokane, WA 99206; (509) 924-7935.

PHYSICIANS WANTED

ORTHOPEDIC SURGEON: Practice opportunity available for Orthopedic Surgeon in association with two Board certified General Surgeons in northwest Iowa. Modern, expanding hospital facilities in growth-oriented communities. Excellent financial and benefit package. Contact J. Dwight Gray, Administrator, Floyd Valley Hospital, Le Mars, IA 51031; (712) 546-7871.

INTERNIST—Wanted, BC or BE Internist to join expanding HMO medical center in Fairfield, California (San Francisco Bay Area). Write to Chief of Department of Medicine, Kaiser Permanente Medical Center, 1550 Gateway Blvd., Fairfield, CA 94533.

LEAVENWORTH, WASHINGTON: Two Board certified Family Physicians seeking additional partners. Small eastern Washington town in beautiful mountain setting. Offices adjacent to community hospital. Flexible hours and scheduling. Contact Patricia Ortiz, MD, or Gregory Steeber, MD, PO Box 9, Leavenworth, WA 98826; (509) 548-5812.

OPHTHALMOLOGIST, Sun Valley, Idaho. Energetic ophthalmologist to establish practice in multispecialty group. Well equipped adjacent hospital. Outstanding setting! Curriculum vitae and references with first letter please. Dr Stephen R. Luber, PO Box 66, Sun Valley, ID 83353.

MEDICAL DIRECTOR needed for busy hospital-affiliated urgent care center in San Francisco. Board certification or eligibility in internal medicine, family practice or emergency medicine is required. Applicant should have experience managing nursing and clerical staff and coordinating physician coverage, and should be able to work closely with marketing and administrative personnel. Please reply to Number 108, Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

NORTHERN SANTA BARBARA COUNTY: Group family practice immediate openings to join dynamic 75 physician multispecialty clinic in primary care branch offices. Full range of Family Practice; OB desirable not necessary. Start July 1986 or earlier. Excellent benefits package. Board certified/eligible. Send CV and letters of recommendation to: Administration, Santa Barbara Medical Foundation Clinic, PO Box 1200, Santa Barbara, CA 93102.

HEAD AND ASSOCIATE HEAD of Clinical Medicine, Student Health Service, Readvertised—SDSU invites applications for Head and Associate Head of Clinical Medicine for two anticipated openings June 1986. Licensed GP, FP or Internists, successful experience with young adult clientele and eligibility for SD licensure required. Submit résumé and three recent letters of recommendation to Don Smith, Administrator of Student Health, 202 West Hall, Box 510, South Dakota State University, Brookings, SD 57007; (605) 688-4157. Deadline is April 1, 1986 or until positions are filled. South Dakota State University is an AA/EEO Employer (female/male).

FAMILY PRACTITIONER needed in northern California town in the Sierra. Join an established practitioner with guaranteed income and great benefits. Contact: Carol Sweig, Western Physicians Registry, 1315 Evans Ave., San Francisco, CA 94124; (415) 826-7676.

CHAIRMAN, DEPARTMENT OF PEDIATRICS, School of Medicine, University of California, San Francisco (UCSF). Qualified candidates are invited to apply for the position of Chairman of the Department of Pediatrics at UCSF School of Medicine. Applicants should send a curriculum vitae, bibliography and the names of four references to Professor Ivan Diamond, Chairman, Pediatrics Search Committee, The Gallo Center, San Francisco General Hospital, Bldg. 1., Room 101, San Francisco, CA 94110. The University of California is an affirmative action, equal opportunity employer. Women and minorities are urged to apply. Applications should be received by April 15, 1986.

PHYSICIANS WANTED

SAN DIEGO STATE UNIVERSITY

Student Health Services. Physician II, 10-month position. Board certification required (Family Practice strongly preferred). Salary range: \$5,026 to \$6,083 per month. Start date: September 1, 1986 or later. AA/EE/O Title IX Employer. Send letter of interest and CV to: Kevin Patrick, MD, MS, Director, Student Health Services, San Diego State University, San Diego, CA 92182.

RHEUMATOLOGIST: Position available immediately with small, growth oriented neuro-musculo-rehabilitation clinic; association with another Rheumatologist. Board certified or eligible. Excellent practice opportunity with all practice costs paid. Superb living conditions on central coast of California. Guaranteed salary with bonus opportunity plus excellent benefit package. Contact and send CV to: David Graham, Administrator, Central Rehabilitation Clinic, Inc., 1334 Marsh St., San Luis Obispo, CA 93401.

FAMILY PRACTICE OPPORTUNITY—Leave the business headaches of medicine behind. Practice quality medicine in group practice setting. Family physician, BE/BC, for group practice in Northern California. Active practice opportunity with country living conveniently located between San Francisco and Sierra Nevada ski resorts. Modern, well equipped hospital minutes away. Moving expenses, salary guarantee. Time available for family and outside activities. Send CV to Dr Lawrence Highman, 199 E. Webster St., Colusa, CA 95932.

FAMILY PRACTITIONER—position available with 35-member multispecialty group on the central coast of California. BC/BE required, excellent practice opportunity; full range of benefits, all practice costs paid, plus immediate shareholder status. Mail CV to: Colin Wells, MD, Recruitment Coordinator, 1235 Osos St., San Luis Obispo, CA 93401. No phone calls please.

VACANCIES EXIST at this GM&S Hospital for three staff physicians. Must be Board certified or Board eligible with a specialty in vascular surgery, internal medicine, or family practice (ambulatory care). Excellent recreation facilities and schools in area. Pleasant climate and ideal living conditions in city of 58,000. No state income tax. Interested physicians should contact David Pennington, (307) 778-7550, ext. 371 or 233.

SOUTHERN CALIFORNIA

CIGNA Healthplans of California, the nation's oldest HMO, seeks Specialists and General Practitioners for career positions in Los Angeles and Orange Counties. Located in close proximity to major teaching centers, we offer the opportunity for continued professional development and rewarding clinical practice. Excellent compensation and benefits including profit sharing. Please send CV to Director/Physician Recruitment, CIGNA Healthplans of California, 700 N. Brand Blvd., Suite 500-49, Glendale, CA 91203.

MEDICAL BUILDING with x-ray and laboratory facilities; has space for Internist, General Surgeon and OB/GYN. Individual renters, or join established partnership. Contact PO Box 369, Ellensburg, WA 98926.

NORTH IDAHO—Excellent summer/winter recreational area. College community. Coeur d'Alene professional medical center has 1,512 square feet attractive, fully-equipped office for sub-lease with option to buy. Independent lab and x-ray department in building. Next door to well-equipped hospital. Send correspondence to Ironwood Medical Center, 920 Ironwood Dr., Coeur d'Alene, ID 83814 or phone Ann Poole at (208) 773-9495.

SITUATIONS WANTED

PHYSICIAN ASSISTANT, certified, seeks permanent position in urgent care, adult ambulatory medicine or clinical research. Duke graduate with six years experience in family/emergency medicine. Love the West! Call Doug Stackhouse, (201) 754-4424.

BOARD CERTIFIED PATHOLOGIST—Twenty-two years experience. All offers considered. Call (805) 832-8083 or write Number 110, Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

PRACTICES AVAILABLE

FAMILY PRACTICE FOR SALE: Retiring, gross over \$225,000. Take over lease. Buy equipment. Ideal location. Next to busy hospital. No OB. Terms. Contact Leonard R. Akland, MD, 227 W. Janss Rd., Ste. 320, Thousand Oaks, CA 91360; (805) 495-0411.

INTERNAL MEDICINE PRACTICE for sale. Available summer or fall 1986. Well established. North area Sacramento. Reply Number 105, Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.

CALIFORNIA: Orthopedics, Urology, Pulmonary, Otolaryngology, Surgery, Cardiology, Family, Internal, Pediatric, OB/GYN, Psychiatric, others. Contact Mary Bradshaw, Practice Broker/Recruiter, 21 Altamount Dr., Orinda, CA 94563; (415) 376-0762.

TIRED OF LIFE in the fast lane? Superb opportunity to buy active established internal medicine practice from female internist. Excellent income. Active medical community. Come to mid-sized city in California's lush central valley. Generous terms. Will introduce. Reply Number 109, Western Journal of Medicine, PO Box 7602, San Francisco, CA 94120-7602.



GENERAL INTERNISTS & FAMILY PRACTITIONERS

FHP has ranked among the nation's leading Health Maintenance Organizations for over 25 years. Due to our continual growth, we are seeking Board eligible/Board certified Internists and Family Practitioners at several of our modern Southern California facilities.

At FHP you will enjoy practicing quality medicine in a progressive group practice environment. We have an excellent compensation package that includes complete malpractice coverage, predictable work schedules, paid vacations and sabbaticals and much more.

For information about immediate or future opportunities, contact FHP Professional Staffing at (800) 446-2255, or (800) 336-2255 in California.

FHP

9900 Talbert Avenue, Fountain Valley, CA 92708

SERVICES

IF YOU ARE setting up a new medical practice or need help with your existing practice, please call Kate North/Medical Office Consultant, (206) 823-5639.

PROFESSIONAL RESUMÉ SERVICES. Curriculum vitae preparation for physicians. All fields. Mailing Services available. Prompt and confidential. Call toll free anytime. 1 (800) 6-CAREER. In PA, (215) 433-4112.

PHYSICIANS—Protect your valuable keys from loss! New low cost unique registered key tags increase safe return. Free details. Write Key Recovery Systems, Box 1572, Bowling Green, KY 42101.

PHYSICIANS/SURGEONS—All specialties sought for quality-oriented, nationwide referral service for medical-legal consultation. Highly rewarding opportunity for qualified experts. Send inquiries to ExpertNet, 2020 West State St., Ste. 164, Milwaukee, WI 53233; (414) 963-8829.

MEDICAL EQUIPMENT

FOR SALE—Used equipment from surgical pathology/cytology lab and office. Excellent condition. Please direct inquiries to PO Box 875, Albuquerque, NM 87103.

REAL ESTATE

MEDICAL BUILDING for lease. 6,500 square feet, x-ray, lab. Close to Civic Center, Bakersfield, CA. Call (805) 327-3830 or (714) 498-6551.

LEGAL COUNSEL



Former Deputy Atty General representing BMOA & Dept. of Health. Now specializing in BMOA investigations and disciplinary actions. Hospital Staff Privilege cases and Defense Malpractice cases thruout Calif.
LAURENCE E. SPITAL, A PROFESSIONAL CORP.
 1200 THIRD AVE., SUITE 1524, SAN DIEGO, CA 92101 (619) 231-4848

MISCELLANEOUS

TALK TO PATIENTS IN EVERYDAY SPANISH!

- Mexican Spanish Pronunciation/Make Friends' cassette & manual: \$13.95 (SATISFACTION GUARANTEED)
- Other cassettes, full tape courses, including course in **MEDICAL SPANISH**
- **INTENSIVE COURSES IN SUNNY BAJA CALIFORNIA**—Weekday, weekend & evening classes—minutes from San Diego
- **CEU's: Calif. BRN #06235**

Call or write for **FREE BROCHURES** today:



CALIFORNIA SPANISH LANGUAGE ASSOCIATION
 189-J Correo Fronterizo, San Ysidro, CA 92073
 (619) 544-0548

SEMINARS

ADVANCED CARDIAC LIFE SUPPORT PROVIDER, RECERTIFICATION AND INSTRUCTOR

Offered quarterly in San Francisco. AHA certified. Pre-ACLS study workshops also available.

CPR Seminars
 833 Market Street, Suite 421
 San Francisco, CA 94103
 (415) 543-7282

HAWAII

Waikiki and/or Maui, Kauai, Big Island
 CME Category I, ACEP and Nursing
 Daily & weekly all year
 For information and catalog call:
800 367-8047, Ext. 110



808 924-4000
 307 Lewers St., PH
 Honolulu, HI 96815


In moderate depression and anxiety

FEELING BETTER FASTER...

OVERNIGHT—SLEEP IMPROVED¹

Sleep improved in 74% after only one h.s. dose in selected patients

FIRST WEEK—OTHER SOMATIC SYMPTOMS MARKEDLY REDUCED¹




FOURTH WEEK—PATIENT COMPLIANCE WAS BETTER²


More than three times as many amitriptyline patients as Limbitrol patients dropped out of therapy because of side effects, although the incidence of side effects was similar. Caution patients against the combined effects of Limbitrol with alcohol or other CNS depressants and about activities requiring complete mental alertness, such as operating machinery or driving a car. In general, limit dosage to lowest effective amount in elderly patients.

References: 1. Data on file, Hoffmann-La Roche Inc., Nutley, NJ. 2. Feighner JP, et al. *Psychopharmacology* 61:217-225, Mar 22, 1979.

Limbitrol[®]

Each tablet contains 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt) 

Limbitrol DS[®]

Each tablet contains 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt) 

A brighter perspective...sooner

Limbitrol[®] @ Tranquilizer-Antidepressant

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of moderate to severe depression associated with moderate to severe anxiety.

Contraindications: Known hypersensitivity to benzodiazepines or tricyclic antidepressants. Do not use with monoamine oxidase (MAO) inhibitors or within 14 days following discontinuation of MAO inhibitors since hyperpyretic crises, severe convulsions and deaths have occurred with concomitant use; then initiate cautiously, gradually increasing dosage until optimal response is achieved. Contraindicated during acute recovery phase following myocardial infarction.

Warnings: Use with great care in patients with history of urinary retention or angle-closure glaucoma. Severe constipation may occur in patients taking tricyclic antidepressants and anticholinergic-type drugs. Closely supervise cardiovascular patients. (Arrhythmias, sinus tachycardia and prolongation of conduction time reported with use of tricyclic antidepressants, especially high doses. Myocardial infarction and stroke reported with use of this class of drugs.) Caution patients about possible combined effects with alcohol and other CNS depressants and against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving).

Usage in Pregnancy: Use of minor tranquilizers during the first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.

Since physical and psychological dependence to chlordiazepoxide have been reported rarely, use caution in administering Limbitrol to addiction-prone individuals or those who might increase dosage; withdrawal symptoms following discontinuation of either component alone have been reported (nausea, headache and malaise for amitriptyline; symptoms [including convulsions] similar to those of barbiturate withdrawal for chlordiazepoxide).

Precautions: Use with caution in patients with a history of seizures, in hyperthyroid patients or those on thyroid medication, and in patients with impaired renal or hepatic function. Because of the possibility of suicide in depressed patients, do not permit easy access to large quantities in these patients. Periodic liver function tests and blood counts are recommended during prolonged treatment. Amitriptyline component may block action of guanethidine or similar antihypertensives. When tricyclic antidepressants are used concomitantly with cimetidine (Tagamet), clinically significant effects have been reported involving delayed elimination and increasing steady state concentrations of the tricyclic drugs. Concomitant use of Limbitrol with other psychotropic drugs has not been evaluated; sedative effects may be additive. Discontinue several days before surgery. Limit concomitant administration of ECT to essential treatment. See Warnings for precautions about pregnancy. Limbitrol should not be taken during the nursing period. Not recommended in children under 12. In the elderly and debilitated, limit to smallest effective dosage to preclude ataxia, oversedation, confusion or anticholinergic effects.

Adverse Reactions: Most frequently reported are those associated with either component alone: drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating. Less frequently occurring reactions include vivid dreams, impotence, tremor, confusion and nasal congestion. Many depressive symptoms including anorexia, fatigue, weakness, restlessness and lethargy have been reported as side effects of both Limbitrol and amitriptyline. Granulocytopenia, jaundice and hepatic dysfunction have been observed rarely.

The following list includes adverse reactions not reported with Limbitrol but requiring consideration because they have been reported with one or both components or closely related drugs:

Cardiovascular: Hypotension, hypertension, tachycardia, palpitations, myocardial infarction, arrhythmias, heart block, stroke.

Psychiatric: Euphoria, apprehension, poor concentration, delusions, hallucinations, hypomania and increased or decreased libido.

Neurologic: Incoordination, ataxia, numbness, tingling and paresthesias of the extremities, extrapyramidal symptoms, syncope, changes in EEG patterns.

Anticholinergic: Disturbance of accommodation, paralytic ileus, urinary retention, dilatation of urinary tract.

Allergic: Skin rash, urticaria, photosensitization, edema of face and tongue, pruritus.

Hematologic: Bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia.

Gastrointestinal: Nausea, epigastric distress, vomiting, anorexia, stomatitis, peculiar taste, diarrhea, black tongue.

Endocrine: Testicular swelling and gynecomastia in the male, breast enlargement, galactorrhea and minor menstrual irregularities in the female, elevation and lowering of blood sugar levels, and syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Other: Headache, weight gain or loss, increased perspiration, urinary frequency, mydriasis, jaundice, alopecia, parotid swelling.

Overdosage: Immediately hospitalize patient suspected of having taken an overdose. Treatment is symptomatic and supportive. I.V. administration of 1 to 3 mg physostigmine salicylate has been reported to reverse the symptoms of amitriptyline poisoning. See complete product information for manifestation and treatment.

Dosage: Individualize according to symptom severity and patient response. Reduce to smallest effective dosage when satisfactory response is obtained. Larger portion of daily dose may be taken at bedtime. Single h.s. dose may suffice for some patients. Lower dosages are recommended for the elderly.

Limbitrol DS (double strength) Tablets, initial dosage of three or four tablets daily in divided doses, increased up to six tablets or decreased to two tablets daily as required. Limbitrol Tablets, initial dosage of three or four tablets daily in divided doses, for patients who do not tolerate higher doses.

How Supplied: Double strength (DS) Tablets, white, film-coated, each containing 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt), and Tablets, blue, film-coated, each containing 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt). Available in bottles of 100 and 500; Tel-E-Dose[®] packages of 100; Prescription Paks of 50.



ROCHE PRODUCTS INC.
Manati, Puerto Rico 00701

In depression and anxiety

CLEARING
SYMPTOMS
FASTER...



Limbitrol[®]

Each tablet contains 5 mg chlordiazepoxide and 12.5 mg amitriptyline (as the hydrochloride salt) (N)

Limbitrol[®] DS

Each tablet contains 10 mg chlordiazepoxide and 25 mg amitriptyline (as the hydrochloride salt) (N)

Once daily *h.s.* for improved compliance

Please see reverse side for references and summary of product information.



Copyright © 1985 by Roche Products Inc. All rights reserved.